Clinical Trial Update: RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

View source ↗

Summary

A clinical trial evaluating radiomic predictors of HER2 status and response to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer with Bone Metastasis

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Radiomic, Radiomics | Status: RECRUITING